Clinical Trial

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated December 28, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-04; most recent amendment 2024-11-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-10-17
Trial Details
NCT Number NCT05856084
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions Herpes Zoster
Enrollment 924 participants
Start Date 2023-05-07
Primary Completion 2024-12-28 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-20